Background This narrative review of osteonecrosis of the jaw in patients with low bone mass
receiving treatment with antiresorptive agents is based on an appraisal of the literature by an …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

Though osteonecrosis of the jaw (ONJ) is temporally‐associated with the use of nitrogen‐
containing bisphosphonates (N‐BPs), a cause‐and‐effect relationship has not yet been …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Osteonecrosis of the jaw (ONJ) is an uncommon condition noted to occur in patients who are
receiving osteoclast-targeted antiresorptive therapy. The incidence of ONJ in patients taking …

Tooth extraction results in alveolar bone resorption and is accompanied by postoperative
swelling and pain. Maresin 1 (MaR1) is a proresolving lipid mediator produced by …

Introduction Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a pathologic
condition of increasing frequency, with a poorly understood pathophysiology and which can …

In 2009, a study group of three Saxon hospitals set up a Saxon register with the aim of
including all patients with bisphosphonate (BP) medication. In addition, specific concepts for …

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a dramatic disintegration of the
jaw that affects patients treated with bisphosphonates (BPs) for diseases characterized by …

Background Proton pump inhibitors, over‐the‐counter drugs taken by millions of patients,
diminish bone accrual. Accordingly, we hypothesized that these drugs could impair bone …